

Colorado HB 19-1131 Disclosure

Qelbree® (Viloxazine)

Supernus Pharmaceuticals, Inc. (Supernus) provides the following information to Colorado prescribers, as required by Colorado House Bill 19-1131.

The pricing information below reflects Supernus Wholesale Acquisition Costs (“WAC”) for the Supernus Pharmaceuticals, Inc. product: Qelbree®. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the prices listed, depending, for example, on how the customer purchases the product, the availability of discounts, the wholesaler/distributor, or other charges.

WAC for Qelbree®

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
Qelbree® (Viloxazine)	17772-0131-30	Capsule 100 MG	\$400.14
Qelbree® (Viloxazine)	17772-0132-30	Capsule 150 MG	\$400.14
Qelbree® (Viloxazine)	17772-0133-30	Capsule 200 MG	\$400.14
Qelbree® (Viloxazine)	17772-0133-60	Capsule 200 MG	\$800.28

Generic versions of Qelbree are not currently available.

For more information on the price disclosure requirements, please contact the Colorado State Board of Pharmacy at:

State Board of Pharmacy
1560 Broadway, Suite 1350
Denver, CO 80202
Ph. (303) 894-7800 | Fax: (303) 894-7692 | Email: dora_pharmacyboard@state.co.us

Qelbree® is a registered trademark of Supernus Pharmaceuticals, Inc.

Copyright© 2026 Supernus All rights reserved.

4/7/2026